ResearcherHunan UniversityActive in the last 2 years

Wenzhi Tan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0924-192X; OpenAlex author ID A5013083086. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113053 ↗
Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. Co-author DOI 10.1016/j.ymthe.2021.08.023 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chaohui Zuo · 2 shared papers, 2022–2025 · strength 0.40
- Paper Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma. DOI 10.1016/j.isci.2025.113053 ↗
- Paper Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. DOI 10.1016/j.ymthe.2021.08.023 ↗
Biaoming Xu · 1 shared paper, 2025 · strength 0.25
- Paper Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma. DOI 10.1016/j.isci.2025.113053 ↗
Shun Deng · 1 shared paper, 2025 · strength 0.25
- Paper Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma. DOI 10.1016/j.isci.2025.113053 ↗
Jung‐Joon Min · 1 shared paper, 2022 · strength 0.16
- Paper Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. DOI 10.1016/j.ymthe.2021.08.023 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.